A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53

Trial Profile

A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs HDM 201 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Planned number of patients changed from 205 to 225.
    • 18 May 2017 Planned primary completion date changed from 30 Apr 2017 to 31 Jul 2017.
    • 17 Mar 2017 Planned End Date changed from 5 Nov 2017 to 14 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top